PURPOSE: To evaluate the effect of the multivitamin Centrum on the development and progression of age-related lens opacities. DESIGN: Clinic-based prospective cohort study. PARTICIPANTS: Four thousand five hundred ninety individuals with at least one natural lens and photographic follow-up (median, 6.3 years) were assessed for development or progression of lens opacities. MAIN OUTCOME MEASURES: Progression of "any" lens opacity or type-specific opacity was ascertained from lens photographs taken at baseline and at annual visits beginning at year 2. METHODS: The Age-Related Eye Disease Study (AREDS) showed no statistically significant effect of a high-dose antioxidant formulation on progression of lens opacities. Centrum also was provided to approximately two thirds of the study participants. Because Centrum use was elective, a logistic regression model of baseline characteristics was used to generate a propensity score for Centrum use. Repeated-measures logistic regression, adjusted for propensity score and other covariates, was used to evaluate associations of Centrum use and lens opacity. RESULTS: Centrum use, adjusted for propensity score and other covariates, was associated with a reduction in "any" lens opacity progression (odds ratio [OR] = 0.84, 95% confidence interval [CI] = 0.72-0.98, P = 0.025). Results for individual lens opacity types suggested that Centrum use was protective for nuclear opacity events (OR = 0.75, 95% CI = 0.61-0.91, P = 0.004). CONCLUSION: Observational data from the AREDS and other studies suggest that use of a multivitamin may delay the progression of lens opacities. A National Eye Institute-sponsored clinical trial scheduled for completion in 2007 will provide additional data on Centrum use and cataract development.
PURPOSE: To evaluate the effect of the multivitamin Centrum on the development and progression of age-related lens opacities. DESIGN: Clinic-based prospective cohort study. PARTICIPANTS: Four thousand five hundred ninety individuals with at least one natural lens and photographic follow-up (median, 6.3 years) were assessed for development or progression of lens opacities. MAIN OUTCOME MEASURES: Progression of "any" lens opacity or type-specific opacity was ascertained from lens photographs taken at baseline and at annual visits beginning at year 2. METHODS: The Age-Related Eye Disease Study (AREDS) showed no statistically significant effect of a high-dose antioxidant formulation on progression of lens opacities. Centrum also was provided to approximately two thirds of the study participants. Because Centrum use was elective, a logistic regression model of baseline characteristics was used to generate a propensity score for Centrum use. Repeated-measures logistic regression, adjusted for propensity score and other covariates, was used to evaluate associations of Centrum use and lens opacity. RESULTS: Centrum use, adjusted for propensity score and other covariates, was associated with a reduction in "any" lens opacity progression (odds ratio [OR] = 0.84, 95% confidence interval [CI] = 0.72-0.98, P = 0.025). Results for individual lens opacity types suggested that Centrum use was protective for nuclear opacity events (OR = 0.75, 95% CI = 0.61-0.91, P = 0.004). CONCLUSION: Observational data from the AREDS and other studies suggest that use of a multivitamin may delay the progression of lens opacities. A National Eye Institute-sponsored clinical trial scheduled for completion in 2007 will provide additional data on Centrum use and cataract development.
Authors: Leo T Chylack; Nicholas P Brown; Anthony Bron; Mark Hurst; Wolfgang Köpcke; Uta Thien; Wolfgang Schalch Journal: Ophthalmic Epidemiol Date: 2002-02 Impact factor: 1.648
Authors: J A Mares-Perlman; B J Lyle; R Klein; A I Fisher; W E Brady; G M VandenLangenberg; J N Trabulsi; M Palta Journal: Arch Ophthalmol Date: 2000-11
Authors: Tanya S Glaser; Lauren E Doss; Grace Shih; Divya Nigam; Robert D Sperduto; Frederick L Ferris; Elvira Agrón; Traci E Clemons; Emily Y Chew Journal: Ophthalmology Date: 2015-05-09 Impact factor: 12.079
Authors: Jessica R Chang; Euna Koo; Elvira Agrón; Joelle Hallak; Traci Clemons; Dimitri Azar; Robert D Sperduto; Frederick L Ferris; Emily Y Chew Journal: Ophthalmology Date: 2011-11 Impact factor: 12.079
Authors: William G Christen; Robert J Glynn; Howard D Sesso; Tobias Kurth; Jean MacFadyen; Vadim Bubes; Julie E Buring; JoAnn E Manson; J Michael Gaziano Journal: Arch Ophthalmol Date: 2010-11
Authors: William G Christen; Robert J Glynn; Joann E Manson; Jean MacFadyen; Vadim Bubes; Miriam Schvartz; Julie E Buring; Howard D Sesso; J Michael Gaziano Journal: Ophthalmology Date: 2013-11-20 Impact factor: 12.079
Authors: Emily Y Chew; John Paul SanGiovanni; Frederick L Ferris; Wai T Wong; Elvira Agron; Traci E Clemons; Robert Sperduto; Ronald Danis; Suresh R Chandra; Barbara A Blodi; Amitha Domalpally; Michael J Elman; Andrew N Antoszyk; Alan J Ruby; David Orth; Susan B Bressler; Gary E Fish; George B Hubbard; Michael L Klein; Thomas R Friberg; Philip J Rosenfeld; Cynthia A Toth; Paul Bernstein Journal: JAMA Ophthalmol Date: 2013-07 Impact factor: 7.389